首页 > 最新文献

World journal of biological chemistry最新文献

英文 中文
Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation. 异基因造血干细胞移植后患者干扰素- γ和白细胞介素-2的变化。
Pub Date : 2022-09-27 DOI: 10.4331/wjbc.v13.i4.72
Malwina Rybicka-Ramos, Mirosław Markiewicz, Aleksandra Suszka-Świtek, Ryszard Wiaderkiewicz, Sylwia Mizia, Monika Dzierżak-Mietła, Krzysztof Białas

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be related to the occurrence of complications, including graft-versus-host disease (GvHD) and infections. The pathogenesis of acute GvHD is connected with T lymphocytes, which identify alloantigens on host's antigen-presenting cells, activate production of interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), and act on the immune effector cells and damage tissues and organs.

Aim: The aim of the study was to investigate and distinguish serum concentration profiles of IFN-gamma and IL-2 within a 30-d period after allo-HSCT.

Methods: We enrolled 62 patients, i.e., 30 (48%) male and 32 (52%) female subjects [median age 49.5 (19-68) years], after allo-HSCT from siblings (n = 12) or unrelated donors (n = 50) due to acute myeloid leukemia with myeloablative conditioning (n = 26; 42%) and with non-myeloablative conditioning (n = 36; 58%). All patients were given standard immunosuppressive therapy with cyclosporin-A and methotrexate and pre-transplant antithymocyte globulin in the unrelated setting. Blood samples were collected pre-transplant before and after (on day -1) the conditioning therapy and on days +2,+4, +6, +10, +20, and +30 after allo-HSCT. Serum levels of IL-2 and IFN-gamma were determined using ELISA.

Results: Patients were divided into four groups depending on the presence of acute GvHD and clinical manifestations of infection. Group I included patients with neither acute GvHD nor infections [n = 15 (24%)], group II consisted of patients with infections without acute GvHD [n = 17 (27%)], group III was comprised of patients with acute GvHD without infections [n = 9 (15%)], and group IV included patients with both acute GvHD and infections [n = 21 (34%)]. IFN-gamma concentrations were higher in Group II than in other groups on days +20 (P = 0.014) and +30 (P = 0.008). Post-hoc tests showed lower concentrations of IFN-gamma on day +30 in groups I (P = 0.039) and IV (P = 0.017) compared to group II. The levels of IL-2 were mostly undetectable.

Conclusion: Serum levels of IFN-gamma following allo-HSCT progressively escalate. High serum levels of IFN-gamma are related to infectious complications rather than acute GvHD. Serum concentrations of IL-2 in most patients are undetectable.

背景:同种异体造血干细胞移植(alloo - hsct)可能与移植物抗宿主病(GvHD)和感染等并发症的发生有关。急性GvHD的发病机制与T淋巴细胞有关,T淋巴细胞识别宿主抗原呈递细胞上的异体抗原,激活干扰素- γ (ifn - γ)和白细胞介素-2 (IL-2)的产生,作用于免疫效应细胞,损伤组织器官。目的:本研究的目的是研究和区分同种异体造血干细胞移植后30天内血清中ifn - γ和IL-2的浓度谱。方法:我们招募了62例患者,即30例(48%)男性和32例(52%)女性受试者[中位年龄49.5(19-68)岁],由于急性骨髓性白血病伴有清髓条件(n = 26),他们接受了来自兄弟姐妹(n = 12)或非亲属供体(n = 50)的同种异体造血干细胞移植(n = 26);42%)和非清髓调节组(n = 36;58%)。所有患者均给予环孢素a和甲氨蝶呤的标准免疫抑制治疗,并在移植前注射抗胸腺细胞球蛋白。在调理治疗前后(第1天)以及同种异体造血干细胞移植后+2、+4、+6、+10、+20和+30天采集移植前血液样本。ELISA法检测血清IL-2、ifn - γ水平。结果:根据急性GvHD的存在和感染的临床表现将患者分为四组。I组为无急性GvHD和感染的患者[n = 15 (24%)], II组为无急性GvHD感染的患者[n = 17 (27%)], III组为无感染的急性GvHD患者[n = 9 (15%)], IV组为既有急性GvHD又有感染的患者[n = 21(34%)]。第20天(P = 0.014)和第30天(P = 0.008), II组ifn - γ浓度高于其他组。事后测试显示,与II组相比,I组(P = 0.039)和IV组(P = 0.017)在第30天的ifn - γ浓度较低。IL-2的水平大多检测不到。结论:同种异体造血干细胞移植后血清ifn - γ水平逐渐升高。血清中ifn - γ的高水平与感染性并发症有关,而与急性GvHD无关。大多数患者的血清IL-2浓度无法检测到。
{"title":"Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation.","authors":"Malwina Rybicka-Ramos,&nbsp;Mirosław Markiewicz,&nbsp;Aleksandra Suszka-Świtek,&nbsp;Ryszard Wiaderkiewicz,&nbsp;Sylwia Mizia,&nbsp;Monika Dzierżak-Mietła,&nbsp;Krzysztof Białas","doi":"10.4331/wjbc.v13.i4.72","DOIUrl":"https://doi.org/10.4331/wjbc.v13.i4.72","url":null,"abstract":"<p><strong>Background: </strong>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be related to the occurrence of complications, including graft-versus-host disease (GvHD) and infections. The pathogenesis of acute GvHD is connected with T lymphocytes, which identify alloantigens on host's antigen-presenting cells, activate production of interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), and act on the immune effector cells and damage tissues and organs.</p><p><strong>Aim: </strong>The aim of the study was to investigate and distinguish serum concentration profiles of IFN-gamma and IL-2 within a 30-d period after allo-HSCT.</p><p><strong>Methods: </strong>We enrolled 62 patients, <i>i.e.</i>, 30 (48%) male and 32 (52%) female subjects [median age 49.5 (19-68) years], after allo-HSCT from siblings (<i>n</i> = 12) or unrelated donors (<i>n</i> = 50) due to acute myeloid leukemia with myeloablative conditioning (<i>n</i> = 26; 42%) and with non-myeloablative conditioning (<i>n</i> = 36; 58%). All patients were given standard immunosuppressive therapy with cyclosporin-A and methotrexate and pre-transplant antithymocyte globulin in the unrelated setting. Blood samples were collected pre-transplant before and after (on day -1) the conditioning therapy and on days +2,+4, +6, +10, +20, and +30 after allo-HSCT. Serum levels of IL-2 and IFN-gamma were determined using ELISA.</p><p><strong>Results: </strong>Patients were divided into four groups depending on the presence of acute GvHD and clinical manifestations of infection. Group I included patients with neither acute GvHD nor infections [<i>n</i> = 15 (24%)], group II consisted of patients with infections without acute GvHD [<i>n</i> = 17 (27%)], group III was comprised of patients with acute GvHD without infections [<i>n</i> = 9 (15%)], and group IV included patients with both acute GvHD and infections [<i>n</i> = 21 (34%)]. IFN-gamma concentrations were higher in Group II than in other groups on days +20 (<i>P</i> = 0.014) and +30 (<i>P</i> = 0.008). Post-hoc tests showed lower concentrations of IFN-gamma on day +30 in groups I (<i>P</i> = 0.039) and IV (<i>P</i> = 0.017) compared to group II. The levels of IL-2 were mostly undetectable.</p><p><strong>Conclusion: </strong>Serum levels of IFN-gamma following allo-HSCT progressively escalate. High serum levels of IFN-gamma are related to infectious complications rather than acute GvHD. Serum concentrations of IL-2 in most patients are undetectable.</p>","PeriodicalId":23691,"journal":{"name":"World journal of biological chemistry","volume":"13 4","pages":"72-82"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/9c/WJBC-13-72.PMC9521416.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40390894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progesterone in gender-affirming therapy of trans women. 跨性别女性性别确认治疗中的孕酮。
Pub Date : 2022-05-27 DOI: 10.4331/wjbc.v13.i3.66
Charalampos Milionis, Ioannis Ilias, Eftychia Koukkou

Progesterone is an endogenous steroid hormone with an important role for the physiology of the female reproductive system and the mammary gland. It has additional significant actions in other tissues, such as the cardiovascular system, the central nervous system, and bones. The present article explores potential clinical implications from the addition of bioidentical progesterone to gender-affirming treatment of trans women. For this purpose, it provides an overview of the physiological action of progesterone in target tissues and speculates on possible benefits for gender transitioning. Progesterone is expected to exert moderate anti-androgen action through suppression of the hypothalamic-pituitary-gonadal axis and inhibition of the conversion of testosterone to dihydrotestosterone. It may also contribute to breast maturation. In the long-term, progesterone could prevent bone loss and protect cardiovascular health. The potential benefits are mainly inferred by extrapolating evidence from biological actions in cisgender women and medical assumptions and hence, clinicians need to be cautious when applying these data into practice. Further research is needed to ascertain the efficacy and safety of progesterone in current hormonal regimens.

孕酮是一种内源性类固醇激素,对女性生殖系统和乳腺的生理学具有重要作用。它在其他组织中具有额外的重要作用,如心血管系统、中枢神经系统和骨骼。本文探讨了在跨性别女性的性别确认治疗中添加生物相同的孕酮的潜在临床意义。为此,它概述了黄体酮在靶组织中的生理作用,并推测了性别转换的可能益处。孕酮有望通过抑制下丘脑-垂体-性腺轴和抑制睾酮转化为二氢睾酮来发挥适度的抗雄激素作用。它也可能有助于乳房成熟。从长远来看,黄体酮可以防止骨质流失,保护心血管健康。潜在的益处主要是通过推断顺性别女性的生物学行为和医学假设的证据来推断的,因此,临床医生在将这些数据应用于实践时需要谨慎。需要进一步的研究来确定黄体酮在当前激素方案中的疗效和安全性。
{"title":"Progesterone in gender-affirming therapy of trans women.","authors":"Charalampos Milionis,&nbsp;Ioannis Ilias,&nbsp;Eftychia Koukkou","doi":"10.4331/wjbc.v13.i3.66","DOIUrl":"10.4331/wjbc.v13.i3.66","url":null,"abstract":"<p><p>Progesterone is an endogenous steroid hormone with an important role for the physiology of the female reproductive system and the mammary gland. It has additional significant actions in other tissues, such as the cardiovascular system, the central nervous system, and bones. The present article explores potential clinical implications from the addition of bioidentical progesterone to gender-affirming treatment of trans women. For this purpose, it provides an overview of the physiological action of progesterone in target tissues and speculates on possible benefits for gender transitioning. Progesterone is expected to exert moderate anti-androgen action through suppression of the hypothalamic-pituitary-gonadal axis and inhibition of the conversion of testosterone to dihydrotestosterone. It may also contribute to breast maturation. In the long-term, progesterone could prevent bone loss and protect cardiovascular health. The potential benefits are mainly inferred by extrapolating evidence from biological actions in cisgender women and medical assumptions and hence, clinicians need to be cautious when applying these data into practice. Further research is needed to ascertain the efficacy and safety of progesterone in current hormonal regimens.</p>","PeriodicalId":23691,"journal":{"name":"World journal of biological chemistry","volume":"13 3","pages":"66-71"},"PeriodicalIF":0.0,"publicationDate":"2022-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8e/58/WJBC-13-66.PMC10558402.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9614858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results 间充质基质细胞递送作为对抗COVID-19的潜在治疗策略:来自体外结果的有希望的证据
Pub Date : 2022-03-27 DOI: 10.4331/wjbc.v13.i2.47
P. Mallis, T. Chatzistamatiou, Zetta Dimou, E. Sarri, E. Georgiou, M. Salagianni, Vasiliki Triantafyllia, E. Andreakos, C. Stavropoulos‐Giokas, E. Michalopoulos
BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic, which was initiated in December 2019. COVID-19 is characterized by a low mortality rate (< 6%); however, this percentage is higher in elderly people and patients with underlying disorders. COVID-19 is characterized by mild to severe outcomes. Currently, several therapeutic strategies are evaluated, such as the use of anti-viral drugs, prophylactic treatment, monoclonal antibodies, and vaccination. Advanced cellular therapies are also investigated, thus representing an additional therapeutic tool for clinicians. Mesenchymal stromal cells (MSCs), which are known for their immunoregulatory properties, may halt the induced cytokine release syndrome mediated by SARS-CoV-2, and can be considered as a potential stem cell therapy. AIM To evaluate the immunoregulatory properties of MSCs, upon stimulation with COVID-19 patient serum. METHODS MSCs derived from the human Wharton’s Jelly (WJ) tissue and bone marrow (BM) were isolated, cryopreserved, expanded, and defined according to the criteria outlined by the International Society for Cellular Therapies. Then, WJ and BM-MSCs were stimulated with a culture medium containing 15% COVID-19 patient serum, 1% penicillin-streptomycin, and 1% L-glutamine for 48 h. The quantification of interleukin (IL)-1 receptor a (Ra), IL-6, IL-10, IL-13, transforming growth factor (TGF)-β1, vascular endothelial growth factor (VEGF)-a, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and indoleamine-2,3-dioxygenase (IDO) was performed using commercial ELISA kits. The expression of HLA-G1, G5, and G7 was evaluated in unstimulated and stimulated WJ and BM-MSCs. Finally, the interactions between MSCs and patients’ macrophages were established using co-culture experiments. RESULTS Thawed WJ and BM-MSCs exhibited a spindle-shaped morphology, successfully differentiated to “osteocytes”, “adipocytes”, and “chondrocytes”, and in flow cytometric analysis were characterized by positivity for CD73, CD90, and CD105 (> 95%) and negativity for CD34, CD45, and HLA-DR (< 2%). Moreover, stimulated WJ and BM-MSCs were characterized by increased cytoplasmic granulation, in comparison to unstimulated cells. The HLA-G isoforms (G1, G5, and G7) were successfully expressed by the unstimulated and stimulated WJ-MSCs. On the other hand, only weak expression of HLA-G1 was identified in BM-MSCs. Stimulated MSCs secreted high levels of IL-1Ra, IL-6, IL-10, IL-13, TGF-β1, FGF, VEGF, PDGF, and IDO in comparison to unstimulated cells (P < 0.05) after 12 and 24 h. Finally, macrophages derived from COVID-19 patients successfully adapted the M2 phenotype after co-culturing with stimulated WJ and BM-MSCs. CONCLUSION WJ and BM-MSCs successfully produced high levels of immunoregulatory agents, which may efficiently modulate the over-activated immune responses of critically ill COVID-19 patients.
背景:严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)是2019年12月开始的2019冠状病毒病(COVID-19)大流行的罪魁祸首。COVID-19的特点是死亡率低(< 6%);然而,这一比例在老年人和有潜在疾病的患者中更高。COVID-19的特点是轻度至重度后果。目前,几种治疗策略被评估,如使用抗病毒药物、预防性治疗、单克隆抗体和疫苗接种。先进的细胞疗法也进行了研究,从而代表了临床医生的额外治疗工具。间充质基质细胞(MSCs)以其免疫调节特性而闻名,可以阻止SARS-CoV-2介导的诱导细胞因子释放综合征,可以被认为是一种潜在的干细胞治疗方法。目的探讨COVID-19患者血清刺激MSCs的免疫调节特性。方法从人沃顿氏水母(WJ)组织和骨髓(BM)中分离MSCs,冷冻保存,扩增,并根据国际细胞治疗学会制定的标准进行定义。然后,用含有15% COVID-19患者血清、1%青霉素-链霉素和1% l -谷氨酰胺的培养基刺激WJ和BM-MSCs 48 h。使用商业ELISA试剂盒定量检测白细胞介素(IL)-1受体a (Ra)、IL-6、IL-10、IL-13、转化生长因子(TGF)-β1、血管内皮生长因子(VEGF)-a、成纤维细胞生长因子(FGF)、血小板衍生生长因子(PDGF)和吲哚胺-2,3-双加氧酶(IDO)。在未刺激和刺激的WJ和BM-MSCs中评估HLA-G1、G5和G7的表达。最后,通过共培养实验建立MSCs与患者巨噬细胞之间的相互作用。结果解冻后的WJ和BM-MSCs呈纺锤形形态,成功分化为“骨细胞”、“脂肪细胞”和“软骨细胞”,流式细胞术分析显示CD73、CD90和CD105阳性(95%),CD34、CD45和HLA-DR阴性(< 2%)。此外,与未受刺激的细胞相比,受刺激的WJ和BM-MSCs的特征是细胞质肉芽增生。未刺激和刺激的WJ-MSCs成功表达了HLA-G亚型G1、G5和G7。另一方面,HLA-G1在BM-MSCs中仅呈弱表达。与未刺激的MSCs相比,刺激后的MSCs在12和24 h后分泌高水平的IL-1Ra、IL-6、IL-10、IL-13、TGF-β1、FGF、VEGF、PDGF和IDO (P < 0.05)。最后,来自COVID-19患者的巨噬细胞与刺激后的WJ和BM-MSCs共培养后成功适应M2表型。结论WJ和BM-MSCs成功产生高水平的免疫调节因子,可能有效调节COVID-19危重症患者过度激活的免疫反应。
{"title":"Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results","authors":"P. Mallis, T. Chatzistamatiou, Zetta Dimou, E. Sarri, E. Georgiou, M. Salagianni, Vasiliki Triantafyllia, E. Andreakos, C. Stavropoulos‐Giokas, E. Michalopoulos","doi":"10.4331/wjbc.v13.i2.47","DOIUrl":"https://doi.org/10.4331/wjbc.v13.i2.47","url":null,"abstract":"BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic, which was initiated in December 2019. COVID-19 is characterized by a low mortality rate (< 6%); however, this percentage is higher in elderly people and patients with underlying disorders. COVID-19 is characterized by mild to severe outcomes. Currently, several therapeutic strategies are evaluated, such as the use of anti-viral drugs, prophylactic treatment, monoclonal antibodies, and vaccination. Advanced cellular therapies are also investigated, thus representing an additional therapeutic tool for clinicians. Mesenchymal stromal cells (MSCs), which are known for their immunoregulatory properties, may halt the induced cytokine release syndrome mediated by SARS-CoV-2, and can be considered as a potential stem cell therapy. AIM To evaluate the immunoregulatory properties of MSCs, upon stimulation with COVID-19 patient serum. METHODS MSCs derived from the human Wharton’s Jelly (WJ) tissue and bone marrow (BM) were isolated, cryopreserved, expanded, and defined according to the criteria outlined by the International Society for Cellular Therapies. Then, WJ and BM-MSCs were stimulated with a culture medium containing 15% COVID-19 patient serum, 1% penicillin-streptomycin, and 1% L-glutamine for 48 h. The quantification of interleukin (IL)-1 receptor a (Ra), IL-6, IL-10, IL-13, transforming growth factor (TGF)-β1, vascular endothelial growth factor (VEGF)-a, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and indoleamine-2,3-dioxygenase (IDO) was performed using commercial ELISA kits. The expression of HLA-G1, G5, and G7 was evaluated in unstimulated and stimulated WJ and BM-MSCs. Finally, the interactions between MSCs and patients’ macrophages were established using co-culture experiments. RESULTS Thawed WJ and BM-MSCs exhibited a spindle-shaped morphology, successfully differentiated to “osteocytes”, “adipocytes”, and “chondrocytes”, and in flow cytometric analysis were characterized by positivity for CD73, CD90, and CD105 (> 95%) and negativity for CD34, CD45, and HLA-DR (< 2%). Moreover, stimulated WJ and BM-MSCs were characterized by increased cytoplasmic granulation, in comparison to unstimulated cells. The HLA-G isoforms (G1, G5, and G7) were successfully expressed by the unstimulated and stimulated WJ-MSCs. On the other hand, only weak expression of HLA-G1 was identified in BM-MSCs. Stimulated MSCs secreted high levels of IL-1Ra, IL-6, IL-10, IL-13, TGF-β1, FGF, VEGF, PDGF, and IDO in comparison to unstimulated cells (P < 0.05) after 12 and 24 h. Finally, macrophages derived from COVID-19 patients successfully adapted the M2 phenotype after co-culturing with stimulated WJ and BM-MSCs. CONCLUSION WJ and BM-MSCs successfully produced high levels of immunoregulatory agents, which may efficiently modulate the over-activated immune responses of critically ill COVID-19 patients.","PeriodicalId":23691,"journal":{"name":"World journal of biological chemistry","volume":"38 1","pages":"47 - 65"},"PeriodicalIF":0.0,"publicationDate":"2022-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81316309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
LIN28A: A multifunctional versatile molecule with future therapeutic potential LIN28A:一种具有未来治疗潜力的多功能分子
Pub Date : 2022-03-27 DOI: 10.4331/wjbc.v13.i2.35
Kenneth Wu, T. Ahmad, R. Eri
An RNA-binding protein, LIN28A was initially discovered in nematodes Caenorhabditis elegans and regulated stem cell differentiation and proliferation. With the aid of mouse models and cancer stem cells models, LIN28A demonstrated a similar role in mammalian stem cells. Subsequent studies revealed LIN28A’s roles in regulating cell cycle and growth, tissue repair, and metabolism, especially glucose metabolism. Through regulation by pluripotency and neurotrophic factors, LIN28A performs these roles through let-7 dependent (binding to let-7) or independent (binding directly to mature mRNA) pathways. Elevated LIN28A levels are associated with cancers such as breast, colon, and ovarian cancers. Overexpressed LIN28A has been implicated in liver diseases and Rett syndrome whereas loss of LIN28A was linked to Parkinson’s disease. LIN28A inhibitors, LIN28A-specific nanobodies, and deubiquitinases targeting LIN28A could be feasible options for cancer treatments while drugs upregulating LIN28A could be used in regenerative therapy for neuropathies. We will review the upstream and downstream signalling pathways of LIN28A and its physiological functions. Then, we will examine current research and gaps in research regarding its mechanisms in conditions such as cancers, liver diseases, and neurological diseases. We will also look at the therapeutic potential of LIN28A in RNA-targeted therapies including small interfering RNAs and RNA-protein interactions.
LIN28A是一种rna结合蛋白,最初是在秀丽隐杆线虫中发现的,并调节干细胞的分化和增殖。在小鼠模型和癌症干细胞模型的帮助下,LIN28A在哺乳动物干细胞中表现出类似的作用。随后的研究揭示了LIN28A在调节细胞周期和生长、组织修复和代谢,特别是葡萄糖代谢中的作用。通过多能性和神经营养因子的调控,LIN28A通过let-7依赖(与let-7结合)或独立(直接与成熟mRNA结合)途径发挥这些作用。LIN28A水平升高与乳腺癌、结肠癌和卵巢癌等癌症有关。LIN28A的过表达与肝脏疾病和Rett综合征有关,而LIN28A的缺失与帕金森病有关。LIN28A抑制剂、LIN28A特异性纳米体和靶向LIN28A的去泛素酶可能是癌症治疗的可行选择,而上调LIN28A的药物可用于神经病变的再生治疗。我们将对LIN28A的上下游信号通路及其生理功能进行综述。然后,我们将检查其在癌症、肝脏疾病和神经系统疾病等疾病中的机制方面的当前研究和研究空白。我们还将研究LIN28A在rna靶向治疗中的治疗潜力,包括小干扰rna和rna -蛋白相互作用。
{"title":"LIN28A: A multifunctional versatile molecule with future therapeutic potential","authors":"Kenneth Wu, T. Ahmad, R. Eri","doi":"10.4331/wjbc.v13.i2.35","DOIUrl":"https://doi.org/10.4331/wjbc.v13.i2.35","url":null,"abstract":"An RNA-binding protein, LIN28A was initially discovered in nematodes Caenorhabditis elegans and regulated stem cell differentiation and proliferation. With the aid of mouse models and cancer stem cells models, LIN28A demonstrated a similar role in mammalian stem cells. Subsequent studies revealed LIN28A’s roles in regulating cell cycle and growth, tissue repair, and metabolism, especially glucose metabolism. Through regulation by pluripotency and neurotrophic factors, LIN28A performs these roles through let-7 dependent (binding to let-7) or independent (binding directly to mature mRNA) pathways. Elevated LIN28A levels are associated with cancers such as breast, colon, and ovarian cancers. Overexpressed LIN28A has been implicated in liver diseases and Rett syndrome whereas loss of LIN28A was linked to Parkinson’s disease. LIN28A inhibitors, LIN28A-specific nanobodies, and deubiquitinases targeting LIN28A could be feasible options for cancer treatments while drugs upregulating LIN28A could be used in regenerative therapy for neuropathies. We will review the upstream and downstream signalling pathways of LIN28A and its physiological functions. Then, we will examine current research and gaps in research regarding its mechanisms in conditions such as cancers, liver diseases, and neurological diseases. We will also look at the therapeutic potential of LIN28A in RNA-targeted therapies including small interfering RNAs and RNA-protein interactions.","PeriodicalId":23691,"journal":{"name":"World journal of biological chemistry","volume":"80 1","pages":"35 - 46"},"PeriodicalIF":0.0,"publicationDate":"2022-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75828695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Increased monoamine oxidase activity and imidazoline binding sites in insulin-resistant adipocytes from obese Zucker rats. 肥胖Zucker大鼠胰岛素抵抗脂肪细胞中单胺氧化酶活性和咪唑啉结合位点增加。
Pub Date : 2022-01-27 DOI: 10.4331/wjbc.v13.i1.15
Christian Carpéné, Luc Marti, Nathalie Morin

Background: Despite overt insulin resistance, adipocytes of genetically obese Zucker rats accumulate the excess of calorie intake in the form of lipids.

Aim: To investigate whether factors can replace or reinforce insulin lipogenic action by exploring glucose uptake activation by hydrogen peroxide, since it is produced by monoamine oxidase (MAO) and semicarbazide-sensitive amine oxidase (SSAO) in adipocytes.

Methods: 3H-2-deoxyglucose uptake (2-DG) was determined in adipocytes from obese and lean rats in response to insulin or MAO and SSAO substrates such as tyramine and benzylamine. 14C-tyramine oxidation and binding of imidazolinic radioligands [3H-Idazoxan, 3H-(2-benzofuranyl)-2-imidazoline] were studied in adipocytes, the liver, and muscle. The influence of in vivo administration of tyramine + vanadium on glucose handling was assessed in lean and obese rats.

Results: 2-DG uptake and lipogenesis stimulation by insulin were dampened in adipocytes from obese rats, when compared to their lean littermates. Tyramine and benzylamine activation of hexose uptake was vanadate-dependent and was also limited, while MAO was increased and SSAO decreased. These changes were adipocyte-specific and accompanied by a greater number of imidazoline I2 binding sites in the obese rat, when compared to the lean. In vitro, tyramine precluded the binding to I2 sites, while in vivo, its administration together with vanadium lowered fasting plasma levels of glucose and triacylglycerols in obese rats.

Conclusion: The adipocytes from obese Zucker rats exhibit increased MAO activity and imidazoline binding site number. However, probably as a consequence of SSAO down-regulation, the glucose transport stimulation by tyramine is decreased as much as that of insulin in these insulin-resistant adipocytes. The adipocyte amine oxidases deserve more studies with respect to their putative contribution to the management of glucose and lipid handling.

背景:尽管有明显的胰岛素抵抗,遗传肥胖的Zucker大鼠的脂肪细胞以脂质形式积累了过量的卡路里摄入。在脂肪细胞、肝脏和肌肉中研究了14c -酪胺氧化和咪唑啉类放射性配体[3H-咪唑嗪,3H-(2-苯并呋喃基)-2-咪唑啉]的结合。在瘦肉大鼠和肥胖大鼠体内,研究酪胺+钒对葡萄糖处理的影响。结果:与瘦鼠相比,肥胖大鼠脂肪细胞中胰岛素对2-DG的摄取和脂肪生成的刺激受到抑制。这些变化是脂肪细胞特异性的,与瘦鼠相比,肥胖大鼠伴有更多的咪唑啉I2结合位点。在体外,酪胺阻止了I2位点的结合,而在体内,酪胺与钒一起给药可以降低肥胖大鼠的空腹血糖和甘油三酯水平。然而,可能是SSAO下调的结果,酪胺对葡萄糖转运的刺激在这些胰岛素抵抗的脂肪细胞中与胰岛素的刺激一样减少。脂肪细胞胺氧化酶在葡萄糖和脂质处理方面的假设贡献值得更多的研究。
{"title":"Increased monoamine oxidase activity and imidazoline binding sites in insulin-resistant adipocytes from obese Zucker rats.","authors":"Christian Carpéné,&nbsp;Luc Marti,&nbsp;Nathalie Morin","doi":"10.4331/wjbc.v13.i1.15","DOIUrl":"https://doi.org/10.4331/wjbc.v13.i1.15","url":null,"abstract":"<p><strong>Background: </strong>Despite overt insulin resistance, adipocytes of genetically obese Zucker rats accumulate the excess of calorie intake in the form of lipids.</p><p><strong>Aim: </strong>To investigate whether factors can replace or reinforce insulin lipogenic action by exploring glucose uptake activation by hydrogen peroxide, since it is produced by monoamine oxidase (MAO) and semicarbazide-sensitive amine oxidase (SSAO) in adipocytes.</p><p><strong>Methods: </strong><sup>3</sup>H-2-deoxyglucose uptake (2-DG) was determined in adipocytes from obese and lean rats in response to insulin or MAO and SSAO substrates such as tyramine and benzylamine. <sup>14</sup>C-tyramine oxidation and binding of imidazolinic radioligands [<sup>3</sup>H-Idazoxan, <sup>3</sup>H-(2-benzofuranyl)-2-imidazoline] were studied in adipocytes, the liver, and muscle. The influence of <i>in vivo</i> administration of tyramine + vanadium on glucose handling was assessed in lean and obese rats.</p><p><strong>Results: </strong>2-DG uptake and lipogenesis stimulation by insulin were dampened in adipocytes from obese rats, when compared to their lean littermates. Tyramine and benzylamine activation of hexose uptake was vanadate-dependent and was also limited, while MAO was increased and SSAO decreased. These changes were adipocyte-specific and accompanied by a greater number of imidazoline I<sub>2</sub> binding sites in the obese rat, when compared to the lean. <i>In vitro</i>, tyramine precluded the binding to I<sub>2</sub> sites, while <i>in vivo</i>, its administration together with vanadium lowered fasting plasma levels of glucose and triacylglycerols in obese rats.</p><p><strong>Conclusion: </strong>The adipocytes from obese Zucker rats exhibit increased MAO activity and imidazoline binding site number. However, probably as a consequence of SSAO down-regulation, the glucose transport stimulation by tyramine is decreased as much as that of insulin in these insulin-resistant adipocytes. The adipocyte amine oxidases deserve more studies with respect to their putative contribution to the management of glucose and lipid handling.</p>","PeriodicalId":23691,"journal":{"name":"World journal of biological chemistry","volume":"13 1","pages":"15-34"},"PeriodicalIF":0.0,"publicationDate":"2022-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/d6/WJBC-13-15.PMC8790288.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39591776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Current understanding of the role of tyrosine kinase 2 signaling in immune responses. 目前对酪氨酸激酶2信号在免疫应答中的作用的了解。
Pub Date : 2022-01-27 DOI: 10.4331/wjbc.v13.i1.1
Ryuta Muromoto, Kenji Oritani, Tadashi Matsuda

Immune system is a complex network that clears pathogens, toxic substrates, and cancer cells. Distinguishing self-antigens from non-self-antigens is critical for the immune cell-mediated response against foreign antigens. The innate immune system elicits an early-phase response to various stimuli, whereas the adaptive immune response is tailored to previously encountered antigens. During immune responses, B cells differentiate into antibody-secreting cells, while naïve T cells differentiate into functionally specific effector cells [T helper 1 (Th1), Th2, Th17, and regulatory T cells]. However, enhanced or prolonged immune responses can result in autoimmune disorders, which are characterized by lymphocyte-mediated immune responses against self-antigens. Signal transduction of cytokines, which regulate the inflammatory cascades, is dependent on the members of the Janus family of protein kinases. Tyrosine kinase 2 (Tyk2) is associated with receptor subunits of immune-related cytokines, such as type I interferon, interleukin (IL)-6, IL-10, IL-12, and IL-23. Clinical studies on the therapeutic effects and the underlying mechanisms of Tyk2 inhibitors in autoimmune or chronic inflammatory diseases are currently ongoing. This review summarizes the findings of studies examining the role of Tyk2 in immune and/or inflammatory responses using Tyk2-deficient cells and mice.

免疫系统是一个复杂的网络,可以清除病原体、有毒底物和癌细胞。区分自身抗原和非自身抗原对于免疫细胞介导的对抗外来抗原的反应至关重要。先天免疫系统对各种刺激产生早期反应,而适应性免疫反应是针对先前遇到的抗原量身定制的。在免疫应答过程中,B细胞分化为抗体分泌细胞,而naïve T细胞分化为功能特异性效应细胞[辅助T细胞1 (Th1)、Th2、Th17和调节性T细胞]。然而,增强或延长的免疫反应可导致自身免疫性疾病,其特征是淋巴细胞介导的针对自身抗原的免疫反应。调节炎症级联反应的细胞因子的信号转导依赖于Janus蛋白激酶家族的成员。酪氨酸激酶2 (Tyk2)与免疫相关细胞因子的受体亚基相关,如I型干扰素、白细胞介素(IL)-6、IL-10、IL-12和IL-23。目前正在进行Tyk2抑制剂在自身免疫性或慢性炎症性疾病中的治疗效果和潜在机制的临床研究。本文综述了利用Tyk2缺陷细胞和小鼠研究Tyk2在免疫和/或炎症反应中的作用的研究结果。
{"title":"Current understanding of the role of tyrosine kinase 2 signaling in immune responses.","authors":"Ryuta Muromoto,&nbsp;Kenji Oritani,&nbsp;Tadashi Matsuda","doi":"10.4331/wjbc.v13.i1.1","DOIUrl":"https://doi.org/10.4331/wjbc.v13.i1.1","url":null,"abstract":"<p><p>Immune system is a complex network that clears pathogens, toxic substrates, and cancer cells. Distinguishing self-antigens from non-self-antigens is critical for the immune cell-mediated response against foreign antigens. The innate immune system elicits an early-phase response to various stimuli, whereas the adaptive immune response is tailored to previously encountered antigens. During immune responses, B cells differentiate into antibody-secreting cells, while naïve T cells differentiate into functionally specific effector cells [T helper 1 (Th1), Th2, Th17, and regulatory T cells]. However, enhanced or prolonged immune responses can result in autoimmune disorders, which are characterized by lymphocyte-mediated immune responses against self-antigens. Signal transduction of cytokines, which regulate the inflammatory cascades, is dependent on the members of the Janus family of protein kinases. Tyrosine kinase 2 (Tyk2) is associated with receptor subunits of immune-related cytokines, such as type I interferon, interleukin (IL)-6, IL-10, IL-12, and IL-23. Clinical studies on the therapeutic effects and the underlying mechanisms of Tyk2 inhibitors in autoimmune or chronic inflammatory diseases are currently ongoing. This review summarizes the findings of studies examining the role of Tyk2 in immune and/or inflammatory responses using <i>Tyk2</i>-deficient cells and mice.</p>","PeriodicalId":23691,"journal":{"name":"World journal of biological chemistry","volume":"13 1","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"2022-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/26/WJBC-13-1.PMC8790287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39894370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Remission is not maintained over 2 years with hematopoietic stem cell transplantation for rheumatoid arthritis: A systematic review with meta-analysis. 类风湿关节炎的造血干细胞移植不能维持2年以上的缓解:一项荟萃分析的系统综述。
Pub Date : 2021-11-27 DOI: 10.4331/wjbc.v12.i6.114
Sathish Muthu, Madhan Jeyaraman, Rajni Ranjan, Saurabh Kumar Jha

Background: Hematopoietic stem cell (HSC) transplantation (HSCT) is being accepted as a standard of care in various inflammatory diseases. The treatment of rheumatoid arthritis (RA) has been closely evolving with the understanding of disease pathogenesis. With the rising resistance to the traditional disease-modifying anti-rheumatic drugs and targeted biological therapy, researchers are in pursuit of other methods for disease management. Since the ultimate goal of the ideal treatment of RA is to restore immune tolerance, HSCT attracts much attention considering its reparative, paracrine, and anti-inflammatory effects. However, a systematic review of studies on HSCT in RA is lacking.

Aim: To investigate the role of HSCT in the management of RA.

Methods: A detailed search of PubMed, Scopus, EMBASE, Cochrane, and the Web of Science databases was made to identify the relevant articles till September 2020 following Cochrane and PRISMA guidelines. We extracted data including the number of patients, source of hematopoietic stem cells, their mobilization and conditioning regimens, results, and complications from the eligible studies. Results were dichotomized into success (ACR 50/70) and failure (ACR 20) based on the improvement from baseline characteristics. The methodological quality of the included studies was also assessed. Analysis was performed using OpenMeta[Analysis] software.

Results: We included 17 studies (1 randomized controlled trial, 11 prospective, and 5 retrospective studies) with 233 patients for analysis. HSCT provided a significantly beneficial overall improvement in the clinical grades of ACR criteria (Z = 11.309, P < 0.001). However, the remission was noted only till 24 mo and later on the significance of the result was lost (Z = 1.737, P = 0.082). A less than 1% treatment-related mortality was noted from the included studies. No major drug-related toxicities were noted in any of the included studies. All patients who underwent allogeneic HSCT received immunosuppression in the conditioning regimen to counteract the graft-vs-host reaction which made them vulnerable to infections. It is noted that the source of hematopoietic stem cells did not play a role in altering the functional outcome and both autologous (Z = 9.972, P < 0.001) and allogenic (Z = 6.978, P < 0.001) sources produced significant improvement in the outcome compared to the pre-operative state despite having a significant heterogeneity among the studies reporting them (I 2 = 99.4, P < 0.001).

Conclusion: Although the available literature is encouraging towards the use of HSCT in refractory cases with significant improvement from baseline till 2 years, the inclusion of HSCT into the standard of care of RA needs further exploration.

背景:造血干细胞(HSC)移植(HSCT)正在被接受为各种炎症性疾病的标准治疗。类风湿关节炎(RA)的治疗随着对其发病机制的了解而密切发展。随着传统抗风湿药物和靶向生物治疗的耐药性上升,研究人员正在寻求其他疾病管理方法。由于RA理想治疗的最终目标是恢复免疫耐受,因此造血干细胞移植因其修复、旁分泌和抗炎作用而备受关注。然而,缺乏对RA中HSCT研究的系统综述。目的:探讨HSCT在类风湿关节炎治疗中的作用。方法:根据Cochrane和PRISMA指南,对PubMed、Scopus、EMBASE、Cochrane和Web of Science数据库进行详细检索,确定截至2020年9月的相关文章。我们从符合条件的研究中提取了包括患者数量、造血干细胞来源、其动员和调理方案、结果和并发症在内的数据。根据基线特征的改善情况,将结果分为成功(ACR 50/70)和失败(ACR 20)。对纳入研究的方法学质量也进行了评估。采用OpenMeta[Analysis]软件进行分析。结果:我们纳入了17项研究(1项随机对照试验,11项前瞻性研究,5项回顾性研究)233例患者进行分析。HSCT在ACR标准的临床分级方面提供了显著有益的总体改善(Z = 11.309, P 0.001)。然而,直到24个月才注意到缓解,之后结果的意义就失去了(Z = 1.737, P = 0.082)。从纳入的研究中发现,与治疗相关的死亡率低于1%。在所有纳入的研究中均未发现主要的药物相关毒性。所有接受同种异体造血干细胞移植的患者在调节方案中接受免疫抑制,以抵消移植物抗宿主反应,这种反应使他们容易受到感染。值得注意的是,造血干细胞的来源并没有改变功能结果,自体(Z = 9.972, P 0.001)和同种异体(Z = 6.978, P 0.001)来源与术前相比,结果都有显著改善,尽管在报道它们的研究中存在显著的异质性(I 2 = 99.4, P 0.001)。结论:尽管现有文献对顽固性病例使用HSCT表示鼓舞,从基线到2年有显著改善,但将HSCT纳入RA的标准治疗还需要进一步探索。
{"title":"Remission is not maintained over 2 years with hematopoietic stem cell transplantation for rheumatoid arthritis: A systematic review with meta-analysis.","authors":"Sathish Muthu,&nbsp;Madhan Jeyaraman,&nbsp;Rajni Ranjan,&nbsp;Saurabh Kumar Jha","doi":"10.4331/wjbc.v12.i6.114","DOIUrl":"https://doi.org/10.4331/wjbc.v12.i6.114","url":null,"abstract":"<p><strong>Background: </strong>Hematopoietic stem cell (HSC) transplantation (HSCT) is being accepted as a standard of care in various inflammatory diseases. The treatment of rheumatoid arthritis (RA) has been closely evolving with the understanding of disease pathogenesis. With the rising resistance to the traditional disease-modifying anti-rheumatic drugs and targeted biological therapy, researchers are in pursuit of other methods for disease management. Since the ultimate goal of the ideal treatment of RA is to restore immune tolerance, HSCT attracts much attention considering its reparative, paracrine, and anti-inflammatory effects. However, a systematic review of studies on HSCT in RA is lacking.</p><p><strong>Aim: </strong>To investigate the role of HSCT in the management of RA.</p><p><strong>Methods: </strong>A detailed search of PubMed, Scopus, EMBASE, Cochrane, and the Web of Science databases was made to identify the relevant articles till September 2020 following Cochrane and PRISMA guidelines. We extracted data including the number of patients, source of hematopoietic stem cells, their mobilization and conditioning regimens, results, and complications from the eligible studies. Results were dichotomized into success (ACR 50/70) and failure (ACR 20) based on the improvement from baseline characteristics. The methodological quality of the included studies was also assessed. Analysis was performed using OpenMeta[Analysis] software.</p><p><strong>Results: </strong>We included 17 studies (1 randomized controlled trial, 11 prospective, and 5 retrospective studies) with 233 patients for analysis. HSCT provided a significantly beneficial overall improvement in the clinical grades of ACR criteria (<i>Z</i> = 11.309, <i>P <</i> 0.001). However, the remission was noted only till 24 mo and later on the significance of the result was lost (<i>Z</i> = 1.737, <i>P</i> = 0.082). A less than 1% treatment-related mortality was noted from the included studies. No major drug-related toxicities were noted in any of the included studies. All patients who underwent allogeneic HSCT received immunosuppression in the conditioning regimen to counteract the graft-<i>vs</i>-host reaction which made them vulnerable to infections. It is noted that the source of hematopoietic stem cells did not play a role in altering the functional outcome and both autologous (<i>Z</i> = 9.972, <i>P <</i> 0.001) and allogenic (<i>Z</i> = 6.978, <i>P <</i> 0.001) sources produced significant improvement in the outcome compared to the pre-operative state despite having a significant heterogeneity among the studies reporting them (<i>I</i> <sup>2</sup> = 99.4, <i>P <</i> 0.001).</p><p><strong>Conclusion: </strong>Although the available literature is encouraging towards the use of HSCT in refractory cases with significant improvement from baseline till 2 years, the inclusion of HSCT into the standard of care of RA needs further exploration.</p>","PeriodicalId":23691,"journal":{"name":"World journal of biological chemistry","volume":"12 6","pages":"114-130"},"PeriodicalIF":0.0,"publicationDate":"2021-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/c3/WJBC-12-114.PMC8637617.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39812396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer's disease. 二肽基肽酶-4抑制剂和胰高血糖素样肽-1类似物通过调节akt信号通路在阿尔茨海默病中的神经保护作用
Pub Date : 2021-11-27 DOI: 10.4331/wjbc.v12.i6.104
Yuka Ikeda, Nozomi Nagase, Ai Tsuji, Yasuko Kitagishi, Satoru Matsuda

Alzheimer's disease (AD) is the most common reason for progressive dementia in the elderly. It has been shown that disorders of the mammalian/mechanistic target of rapamycin (mTOR) signaling pathways are related to the AD. On the other hand, diabetes mellitus (DM) is a risk factor for the cognitive dysfunction. The pathogenesis of the neuronal impairment caused by diabetic hyperglycemia is intricate, which contains neuro-inflammation and/or neurodegeneration and dementia. Glucagon-like peptide-1 (GLP1) is interesting as a possible link between metabolism and brain impairment. Modulation of GLP1 activity can influence amyloid-beta peptide aggregation via the phosphoinositide-3 kinase/AKT/mTOR signaling pathway in AD. The GLP1 receptor agonists have been shown to have favorable actions on the brain such as the improvement of neurological deficit. They might also exert a beneficial effect with refining learning and memory on the cognitive impairment induced by diabetes. Recent experimental and clinical evidence indicates that dipeptidyl-peptidase-4 (DPP4) inhibitors, being currently used for DM therapy, may also be effective for AD treatment. The DPP-4 inhibitors have demonstrated neuroprotection and cognitive improvements in animal models. Although further studies for mTOR, GLP1, and DPP4 signaling pathways in humans would be intensively required, they seem to be a promising approach for innovative AD-treatments. We would like to review the characteristics of AD pathogenesis, the key roles of mTOR in AD and the preventive and/ or therapeutic suggestions of directing the mTOR signaling pathway.

阿尔茨海默病(AD)是老年人进行性痴呆的最常见原因。研究表明,哺乳动物/机制靶雷帕霉素(mTOR)信号通路的紊乱与AD有关。另一方面,糖尿病(DM)是认知功能障碍的危险因素。糖尿病性高血糖引起的神经元损伤的发病机制是复杂的,包括神经炎症和/或神经退行性变和痴呆。胰高血糖素样肽-1 (GLP1)作为代谢和脑损伤之间的可能联系而引人关注。GLP1活性的调节可以通过磷酸肌苷-3激酶/AKT/mTOR信号通路影响AD中淀粉样蛋白- β肽的聚集。GLP1受体激动剂已被证明对大脑有良好的作用,如改善神经功能缺陷。它们也可能在改善由糖尿病引起的认知障碍的学习和记忆方面发挥有益的作用。最近的实验和临床证据表明,目前用于糖尿病治疗的二肽基肽酶-4 (DPP4)抑制剂也可能对阿尔茨海默病有效。DPP-4抑制剂在动物模型中显示出神经保护和认知改善。尽管对人类mTOR, GLP1和DPP4信号通路的进一步研究将是非常必要的,但它们似乎是一种有希望的创新ad治疗方法。本文就阿尔茨海默病的发病特点、mTOR在阿尔茨海默病中的关键作用以及指导mTOR信号通路的预防和/或治疗建议进行综述。
{"title":"Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs <i>via</i> the modulation of AKT-signaling pathway in Alzheimer's disease.","authors":"Yuka Ikeda,&nbsp;Nozomi Nagase,&nbsp;Ai Tsuji,&nbsp;Yasuko Kitagishi,&nbsp;Satoru Matsuda","doi":"10.4331/wjbc.v12.i6.104","DOIUrl":"https://doi.org/10.4331/wjbc.v12.i6.104","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is the most common reason for progressive dementia in the elderly. It has been shown that disorders of the mammalian/mechanistic target of rapamycin (mTOR) signaling pathways are related to the AD. On the other hand, diabetes mellitus (DM) is a risk factor for the cognitive dysfunction. The pathogenesis of the neuronal impairment caused by diabetic hyperglycemia is intricate, which contains neuro-inflammation and/or neurodegeneration and dementia. Glucagon-like peptide-1 (GLP1) is interesting as a possible link between metabolism and brain impairment. Modulation of GLP1 activity can influence amyloid-beta peptide aggregation <i>via</i> the phosphoinositide-3 kinase/AKT/mTOR signaling pathway in AD. The GLP1 receptor agonists have been shown to have favorable actions on the brain such as the improvement of neurological deficit. They might also exert a beneficial effect with refining learning and memory on the cognitive impairment induced by diabetes. Recent experimental and clinical evidence indicates that dipeptidyl-peptidase-4 (DPP4) inhibitors, being currently used for DM therapy, may also be effective for AD treatment. The DPP-4 inhibitors have demonstrated neuroprotection and cognitive improvements in animal models. Although further studies for mTOR, GLP1, and DPP4 signaling pathways in humans would be intensively required, they seem to be a promising approach for innovative AD-treatments. We would like to review the characteristics of AD pathogenesis, the key roles of mTOR in AD and the preventive and/ or therapeutic suggestions of directing the mTOR signaling pathway.</p>","PeriodicalId":23691,"journal":{"name":"World journal of biological chemistry","volume":"12 6","pages":"104-113"},"PeriodicalIF":0.0,"publicationDate":"2021-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/2b/WJBC-12-104.PMC8637616.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39812395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Proteomics: Concepts and applications in human medicine. 蛋白质组学:概念及其在人类医学中的应用。
Pub Date : 2021-09-27 DOI: 10.4331/wjbc.v12.i5.57
Safa Al-Amrani, Zaaima Al-Jabri, Adhari Al-Zaabi, Jalila Alshekaili, Murtadha Al-Khabori

Proteomics is the complete evaluation of the function and structure of proteins to understand an organism's nature. Mass spectrometry is an essential tool that is used for profiling proteins in the cell. However, biomarker discovery remains the major challenge of proteomics because of their complexity and dynamicity. Therefore, combining the proteomics approach with genomics and bioinformatics will provide an understanding of the information of biological systems and their disease alteration. However, most studies have investigated a small part of the proteins in the blood. This review highlights the types of proteomics, the available proteomic techniques, and their applications in different research fields.

蛋白质组学是对蛋白质功能和结构的完整评估,以了解生物体的性质。质谱分析是分析细胞中蛋白质的重要工具。然而,由于生物标志物的复杂性和动态性,它们的发现仍然是蛋白质组学的主要挑战。因此,将蛋白质组学方法与基因组学和生物信息学相结合,将提供对生物系统及其疾病变化信息的理解。然而,大多数研究只调查了血液中的一小部分蛋白质。本文综述了蛋白质组学的类型、现有的蛋白质组学技术及其在不同研究领域的应用。
{"title":"Proteomics: Concepts and applications in human medicine.","authors":"Safa Al-Amrani,&nbsp;Zaaima Al-Jabri,&nbsp;Adhari Al-Zaabi,&nbsp;Jalila Alshekaili,&nbsp;Murtadha Al-Khabori","doi":"10.4331/wjbc.v12.i5.57","DOIUrl":"https://doi.org/10.4331/wjbc.v12.i5.57","url":null,"abstract":"<p><p>Proteomics is the complete evaluation of the function and structure of proteins to understand an organism's nature. Mass spectrometry is an essential tool that is used for profiling proteins in the cell. However, biomarker discovery remains the major challenge of proteomics because of their complexity and dynamicity. Therefore, combining the proteomics approach with genomics and bioinformatics will provide an understanding of the information of biological systems and their disease alteration. However, most studies have investigated a small part of the proteins in the blood. This review highlights the types of proteomics, the available proteomic techniques, and their applications in different research fields.</p>","PeriodicalId":23691,"journal":{"name":"World journal of biological chemistry","volume":"12 5","pages":"57-69"},"PeriodicalIF":0.0,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/58/WJBC-12-57.PMC8473418.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39527982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 32
Alcoholic liver disease: Current insights into cellular mechanisms. 酒精性肝病:当前对细胞机制的认识
Pub Date : 2021-09-27 DOI: 10.4331/wjbc.v12.i5.87
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B Patel

Alcoholic liver disease (ALD) due to chronic alcohol consumption is a significant global disease burden and a leading cause of mortality. Alcohol abuse induces a myriad of aberrant changes in hepatocytes at both the cellular and molecular level. Although the disease spectrum of ALD is widely recognized, the precise triggers for disease progression are still to be fully elucidated. Oxidative stress, mitochondrial dysfunction, gut dysbiosis and altered immune system response plays an important role in disease pathogenesis, triggering the activation of inflammatory pathways and apoptosis. Despite many recent clinical studies treatment options for ALD are limited, especially at the alcoholic hepatitis stage. We have therefore reviewed some of the key pathways involved in the pathogenesis of ALD and highlighted current trials for treating patients.

慢性饮酒引起的酒精性肝病(ALD)是一项重大的全球疾病负担,也是导致死亡的主要原因。酒精滥用在细胞和分子水平上诱导肝细胞发生无数的异常变化。虽然ALD的疾病谱系已被广泛认识,但疾病进展的确切触发因素仍有待充分阐明。氧化应激、线粒体功能障碍、肠道生态失调和免疫系统反应改变在疾病发病机制中发挥重要作用,引发炎症途径的激活和细胞凋亡。尽管最近有许多临床研究表明ALD的治疗选择是有限的,特别是在酒精性肝炎阶段。因此,我们回顾了ALD发病机制中涉及的一些关键途径,并强调了目前治疗患者的试验。
{"title":"Alcoholic liver disease: Current insights into cellular mechanisms.","authors":"Lucy Petagine,&nbsp;Mohammed Gulrez Zariwala,&nbsp;Vinood B Patel","doi":"10.4331/wjbc.v12.i5.87","DOIUrl":"https://doi.org/10.4331/wjbc.v12.i5.87","url":null,"abstract":"<p><p>Alcoholic liver disease (ALD) due to chronic alcohol consumption is a significant global disease burden and a leading cause of mortality. Alcohol abuse induces a myriad of aberrant changes in hepatocytes at both the cellular and molecular level. Although the disease spectrum of ALD is widely recognized, the precise triggers for disease progression are still to be fully elucidated. Oxidative stress, mitochondrial dysfunction, gut dysbiosis and altered immune system response plays an important role in disease pathogenesis, triggering the activation of inflammatory pathways and apoptosis. Despite many recent clinical studies treatment options for ALD are limited, especially at the alcoholic hepatitis stage. We have therefore reviewed some of the key pathways involved in the pathogenesis of ALD and highlighted current trials for treating patients.</p>","PeriodicalId":23691,"journal":{"name":"World journal of biological chemistry","volume":"12 5","pages":"87-103"},"PeriodicalIF":0.0,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e0/46/WJBC-12-87.PMC8473419.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39527984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
期刊
World journal of biological chemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1